摘要：
Background In recent years, it has been discovered that the production of a certain percentage of mutant P53 proteins—with increased stability—in B-cell chronic lymphocytic leukemia (B-CLL) contributes to carcinogenesis. Methods Using the enzyme-linked immunosorbent assay (ELISA) technique, the frequency of P53 protein expression was analyzed in 20 representative patients diagnosed with CLL-B to investigate the relationship between P53 protein levels at different disease stages and patient survival. The monoclonal P53 antibody, PAb 240, which recognizes both mutant and wild-type P53 under denaturing conditions, was used in the ELISA. PAb 240 detects an epitope that is structurally hidden in the P53 wild-type conformation that becomes exposed upon denaturation or in mutant P53 conformations where point mutations in the TP53 gene alter the terminal structure of the protein. Results Of the 20 patients studied, 14 were men aged 55–85 years and 6 were women aged 39–85 years. Patients were undergoing cytostatic and immunotherapy treatment specific to CLL.
• Male P53 protein concentrations (μg/dL): 20, 15, 18, 40, 10, 12, 14, 60, 30, 10, 13, 13, 5, 10, 15, 12. • Women P53 protein concentrations (μg/dL): 140, 30, 13, 10. Statistical Interpretations The probability index (NORMDIST) was calculated at P = 0.034. The reference interval was established between 10 and 40 μg/dL (mean = 24.5 μg/dL). Pathologically elevated values reflecting mutant P53 protein concentrations indicate the increased frequency of mutant P53 in B-CLL. These levels were higher in men than in women, with a male-to-female ratio of 2:1, consistent with findings reported in the specialized literature. Conclusions In the context of B-CLL, a simple and inexpensive ELISA method proves useful for identifying patients who may be considered candidates for personalized therapeutic strategies, particularly in the presence of the mutant P53 protein isoform.
欢迎来到三峡大学图书馆！
中文科技期刊
详细信息
